It rarely starts in a clinic.
More often, it begins quietly. A night of broken sleep. A heat wave that makes no sense. A feeling that something is shifting, but you cannot quite name it yet.
And then, almost reluctantly, the question appears.
Should I be thinking about Menopause Hormone Therapy?
Not as an abstract idea. But personally.
That is where this conversation actually belongs.
Strip away the terminology, and Menopause Hormone Therapy, or MHT, is not complicated.
It is about giving the body back a small, measured amount of what it is gradually losing.
Primarily estrogen. Sometimes progesterone alongside it.
Because what declines during menopause is not just a hormone level on paper. It is regulation itself. Temperature control. Sleep depth. Bone renewal. Even the way the brain processes stress.
MHT does not “reverse” menopause. It steadies the transition.
(Medscape).
You’ll notice two terms used often. HRT and MHT.
In practice, they refer to the same treatment. But language has evolved.
The term Menopause Hormone Therapy is now preferred in many global guidelines because it is more specific. It clearly situates the therapy within menopause, rather than hormone treatments used for other conditions.
In India, however, both terms continue to be used interchangeably. You may hear HRT more commonly in clinics, while medical literature increasingly leans toward MHT.
(Mirorpedia).
This is one area where medicine is not ambiguous.
When it comes to vasomotor symptoms like hot flashes and night sweats, estrogen therapy is consistently the most effective option available.
Not marginally better. Significantly better.
Multiple global studies, including those referenced by the North American Menopause Society, show clear reductions in both frequency and intensity.
One of the most important insights in recent years is not about what MHT does, but when it is started.
Women who begin therapy closer to menopause, typically within ten years, often experience a more favourable balance of benefits and risks.
Start much later, and the equation can shift.
It sounds like a small detail. It isn’t.
Bone loss during menopause is subtle. You do not feel it happening.
But it accelerates.
Estrogen plays a direct role in maintaining bone density, and its decline leaves bones more vulnerable over time.
MHT has been shown to slow this process and, in many cases, reduce fracture risk. This is one of the reasons it remains part of the FDA’s recognised approach to postmenopausal osteoporosis prevention.
This is where most women pause. And understandably so.
Yes, Menopause Hormone Therapy carries risks. But they are not the same for everyone.
They depend on:
• Age
• When therapy begins
• Personal medical history
• The type and form of hormones used
For example, the risk profile of a woman starting therapy at 50 is very different from someone starting at 65.
The nuance matters. Without it, the conversation becomes unnecessarily alarming.
Not all hormone therapy behaves the same way in the body.
Oral estrogen passes through the liver first. This can influence clotting factors in certain individuals.
Transdermal estrogen, delivered through patches or gels, bypasses the liver and often presents a different risk profile.
These distinctions are not minor. They are central to how therapy is tailored.
| Therapy Type | How It Is Taken | Why It Is Used | What to Keep in Mind |
|---|---|---|---|
| Oral estrogen | Tablet | Ease and familiarity | May affect clotting pathways |
| Transdermal estrogen | Patch or gel | Stable absorption | Skin tolerance varies |
| Combined therapy | Estrogen plus progesterone | Protects uterus | Needs careful balance |
| Local estrogen | Vaginal creams or tablets | Targets dryness | Minimal systemic impact |
While often discussed for hot flashes, MHT also touches areas that are less visible.
Sleep, for instance, can deepen. Mood may stabilise. Brain fog may lift slightly for some women.
Not dramatically. Not universally. But enough to be meaningful.
It is not a mental health treatment. But it does intersect with how we feel.
There is no universal recommendation here.
Women with certain medical histories, such as specific cancers or clotting disorders, may not be ideal candidates for MHT.
This is where individual evaluation becomes non-negotiable.
A good clinician does not just prescribe. They assess.
For years, the conversation around HRT risks has been shaped by early interpretations of the Women’s Health Initiative study.
What followed was caution. Often excessive caution.
But over time, reanalysis has brought clarity. Risk varies significantly based on age, timing, and type of therapy.
The science has evolved.
Public perception, in many cases, has not caught up.
The FDA does not dismiss MHT, nor does it position it casually.
Its guidance is precise:
• Use the lowest effective dose
• For the shortest duration needed
• Personalise treatment based on the individual
This is not restrictive. It is responsible medicine.
(FDA).
Hormone therapy is only one part of the picture. During perimenopause, when fluctuations are often unpredictable, Miror Bliss supports emotional balance, sleep stability, and daily resilience.
In postmenopause, Miror Thrive focuses on sustained energy, metabolic health, and recovery, which become more relevant over time.
For women beyond their 60s, Miror MILY offers a gentler, long-term approach to vitality, bone support, and overall wellbeing.
These are not substitutes for medical care. They are complementary layers of support.
For women considering Menopause Hormone Therapy, clarity is often harder to access than information.
Miror’s HRT Centre of Excellence brings together clinical expertise, global protocols, and India-specific context to help women navigate this decision with confidence.
From understanding HRT benefits to evaluating risks and choosing the right form, the approach is deeply personalised.
Because no two women arrive at this decision from the same place.
It unfolds gradually. A question here. A conversation there. Sometimes a hesitation that takes time to resolve.
What matters is not arriving at a yes or no.
It is arriving at a decision that feels informed, grounded, and truly yours.
You do not have to navigate this alone.
Inside the Miror Community, women are learning, asking questions, and finding clarity through expert guidance and shared experiences.
Join here: https://tinyurl.com/mirorc3
Menopause Hormone Therapy (MHT) involves replacing declining hormones, mainly estrogen and sometimes progesterone, to help manage menopause symptoms. It works by stabilising the body’s response to hormonal changes, improving symptoms like hot flashes, night sweats, and sleep disturbances.
Yes, MHT and HRT generally refer to the same treatment. The term Menopause Hormone Therapy is now preferred in medical literature because it specifically refers to hormone therapy used during menopause, while HRT is a broader term used in general practice, including in India.
The primary benefits of Menopausal Hormone Therapy include relief from hot flashes, reduced night sweats, improved sleep quality, and protection against bone loss. It is considered the most effective treatment for moderate to severe menopause symptoms when used appropriately.
HRT risks vary depending on age, timing, and individual health history. Potential risks may include blood clots, stroke, or breast cancer in certain cases. However, for many women starting therapy early in menopause, the overall risk profile is lower than previously believed.
MHT may not be suitable for women with a history of hormone-sensitive cancers, blood clotting disorders, or certain cardiovascular conditions. A personalised medical evaluation is essential before starting therapy.
